Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
NCT04610515 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6000
Last updated 2025-11-14
Summary
The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) study is a CDC-funded COVID-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have suspected COVID symptoms at the time of their test. Participants will complete short online surveys every 3 months for 18 months, share information about their health using a secure web-based platform, and are compensated for their time.
Conditions
- Covid19
- ME/CFS
- SARS COV2
- Novel Coronavirus Infection
- Neurocognitive Disorders
- Cardiovascular Diseases
Sponsors & Collaborators
-
Yale University
collaborator OTHER - collaborator OTHER
-
Thomas Jefferson University
collaborator OTHER -
University of California, Los Angeles
collaborator OTHER -
University of California, San Francisco
collaborator OTHER -
University of Texas Southwestern Medical Center
collaborator OTHER -
The University of Texas Health Science Center, Houston
collaborator OTHER -
Rush University Medical Center
lead OTHER
Principal Investigators
-
Michael Gottlieb, MD · Rush University Medical Center
-
Robert A Weinstein, MD · Rush University Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-15
- Primary Completion
- 2024-08-31
- Completion
- 2025-10-31
Countries
- United States
Study Locations
More Related Trials
-
SARS-CoV-2 Infection in COVID-19 Vaccinated Patients
NCT05060939 ·Status: COMPLETED ·Phase: NA
-
Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers
NCT04659941 ·Status: UNKNOWN ·Phase: PHASE2
-
French COVID Cohort
NCT04262921 ·Status: ACTIVE_NOT_RECRUITING
-
Immune Response and Risk of Serious Infection to SARS-Cov2
NCT04410432 ·Status: COMPLETED
-
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
NCT04832932 ·Status: ACTIVE_NOT_RECRUITING
-
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
NCT04461379 ·Status: UNKNOWN ·Phase: PHASE3
-
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
NCT00814151 ·Status: COMPLETED
-
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
NCT04353518 ·Status: UNKNOWN ·Phase: PHASE3
-
Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives
NCT01184339 ·Status: COMPLETED
-
Arginine Replacement Therapy in COVID-19
NCT05855330 ·Status: RECRUITING ·Phase: PHASE2
-
COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2
NCT04318314 ·Status: UNKNOWN
-
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test (ASPIRE-2)
NCT05506618 ·Status: UNKNOWN ·Phase: NA
-
Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
NCT06334731 ·Status: COMPLETED
-
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)
NCT00980980 ·Status: COMPLETED ·Phase: NA
-
COVID-19 Vaccination AZV 2021-2023
NCT05589233 ·Status: COMPLETED
-
Tocilizumab in Coronavirus-19 Positive Patients
NCT04423042 ·Status: UNKNOWN ·Phase: PHASE3
-
Dysbiosis & Long COVID
NCT06825819 ·Status: RECRUITING
-
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
NCT05256316 ·Status: COMPLETED
-
PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)
NCT04613310 ·Status: COMPLETED ·Phase: NA
-
TOcilizumab and Covid-19 : Risk of Severe INfection
NCT05017441 ·Status: UNKNOWN
-
Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill
NCT04358809 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of Antibody Tests for COVID-19
NCT04360954 ·Status: COMPLETED
-
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
NCT06057025 ·Status: UNKNOWN ·Phase: PHASE3
-
Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.
NCT04362124 ·Status: WITHDRAWN ·Phase: PHASE3
-
Microbial Infection and AMR in Hospitalized Patients With Covid 19
NCT04479982 ·Status: UNKNOWN